Editorial
Imperfect Pharmacovigilance
Abstract
In their accompanying article, Vrettos et al1 report a case of severe thrombocytopenia in a 65-year-old woman that was associated with the use of rosuvastatin for treatment of dyslipidemia. The reported adverse event did not result in a serious adverse clinical outcome and resolved with the discontinuation of the culprit medication. Despite the patient's fortunate outcome, we should recall that she was being treated pharmacologically for dyslipidemia, in the context of which only her age appears to be a traditional cardiovascular risk factor. This patient's 10-year risk of cardiovascular event, although not precisely known based on the information provided, was not likely to have been greater than the 20% benchmark necessitating intensive therapy.2This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.